Cargando…

Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity

Abnormal alteration of bone morphogenetic protein (BMP) signaling is implicated in many types of diseases including cancer and heterotopic ossifications. Hence, small molecules targeting BMP type I receptors (BMPRI) to interrupt BMP signaling are believed to be an effective approach to treat these d...

Descripción completa

Detalles Bibliográficos
Autores principales: Alsamarah, Abdelaziz, LaCuran, Alecander E., Oelschlaeger, Peter, Hao, Jijun, Luo, Yun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489870/
https://www.ncbi.nlm.nih.gov/pubmed/26133550
http://dx.doi.org/10.1371/journal.pone.0132221
_version_ 1782379434594009088
author Alsamarah, Abdelaziz
LaCuran, Alecander E.
Oelschlaeger, Peter
Hao, Jijun
Luo, Yun
author_facet Alsamarah, Abdelaziz
LaCuran, Alecander E.
Oelschlaeger, Peter
Hao, Jijun
Luo, Yun
author_sort Alsamarah, Abdelaziz
collection PubMed
description Abnormal alteration of bone morphogenetic protein (BMP) signaling is implicated in many types of diseases including cancer and heterotopic ossifications. Hence, small molecules targeting BMP type I receptors (BMPRI) to interrupt BMP signaling are believed to be an effective approach to treat these diseases. However, lack of understanding of the molecular determinants responsible for the binding selectivity of current BMP inhibitors has been a big hindrance to the development of BMP inhibitors for clinical use. To address this issue, we carried out in silico experiments to test whether computational methods can reproduce and explain the high selectivity of a small molecule BMP inhibitor DMH1 on BMPRI kinase ALK2 vs. the closely related TGF-β type I receptor kinase ALK5 and vascular endothelial growth factor receptor type 2 (VEGFR2) tyrosine kinase. We found that, while the rigid docking method used here gave nearly identical binding affinity scores among the three kinases; free energy perturbation coupled with Hamiltonian replica-exchange molecular dynamics (FEP/H-REMD) simulations reproduced the absolute binding free energies in excellent agreement with experimental data. Furthermore, the binding poses identified by FEP/H-REMD led to a quantitative analysis of physical/chemical determinants governing DMH1 selectivity. The current work illustrates that small changes in the binding site residue type (e.g. pre-hinge region in ALK2 vs. ALK5) or side chain orientation (e.g. Tyr219 in caALK2 vs. wtALK2), as well as a subtle structural modification on the ligand (e.g. DMH1 vs. LDN193189) will cause distinct binding profiles and selectivity among BMP inhibitors. Therefore, the current computational approach represents a new way of investigating BMP inhibitors. Our results provide critical information for designing exclusively selective BMP inhibitors for the development of effective pharmacotherapy for diseases caused by aberrant BMP signaling.
format Online
Article
Text
id pubmed-4489870
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-44898702015-07-15 Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity Alsamarah, Abdelaziz LaCuran, Alecander E. Oelschlaeger, Peter Hao, Jijun Luo, Yun PLoS One Research Article Abnormal alteration of bone morphogenetic protein (BMP) signaling is implicated in many types of diseases including cancer and heterotopic ossifications. Hence, small molecules targeting BMP type I receptors (BMPRI) to interrupt BMP signaling are believed to be an effective approach to treat these diseases. However, lack of understanding of the molecular determinants responsible for the binding selectivity of current BMP inhibitors has been a big hindrance to the development of BMP inhibitors for clinical use. To address this issue, we carried out in silico experiments to test whether computational methods can reproduce and explain the high selectivity of a small molecule BMP inhibitor DMH1 on BMPRI kinase ALK2 vs. the closely related TGF-β type I receptor kinase ALK5 and vascular endothelial growth factor receptor type 2 (VEGFR2) tyrosine kinase. We found that, while the rigid docking method used here gave nearly identical binding affinity scores among the three kinases; free energy perturbation coupled with Hamiltonian replica-exchange molecular dynamics (FEP/H-REMD) simulations reproduced the absolute binding free energies in excellent agreement with experimental data. Furthermore, the binding poses identified by FEP/H-REMD led to a quantitative analysis of physical/chemical determinants governing DMH1 selectivity. The current work illustrates that small changes in the binding site residue type (e.g. pre-hinge region in ALK2 vs. ALK5) or side chain orientation (e.g. Tyr219 in caALK2 vs. wtALK2), as well as a subtle structural modification on the ligand (e.g. DMH1 vs. LDN193189) will cause distinct binding profiles and selectivity among BMP inhibitors. Therefore, the current computational approach represents a new way of investigating BMP inhibitors. Our results provide critical information for designing exclusively selective BMP inhibitors for the development of effective pharmacotherapy for diseases caused by aberrant BMP signaling. Public Library of Science 2015-07-02 /pmc/articles/PMC4489870/ /pubmed/26133550 http://dx.doi.org/10.1371/journal.pone.0132221 Text en © 2015 Alsamarah et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Alsamarah, Abdelaziz
LaCuran, Alecander E.
Oelschlaeger, Peter
Hao, Jijun
Luo, Yun
Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity
title Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity
title_full Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity
title_fullStr Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity
title_full_unstemmed Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity
title_short Uncovering Molecular Bases Underlying Bone Morphogenetic Protein Receptor Inhibitor Selectivity
title_sort uncovering molecular bases underlying bone morphogenetic protein receptor inhibitor selectivity
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489870/
https://www.ncbi.nlm.nih.gov/pubmed/26133550
http://dx.doi.org/10.1371/journal.pone.0132221
work_keys_str_mv AT alsamarahabdelaziz uncoveringmolecularbasesunderlyingbonemorphogeneticproteinreceptorinhibitorselectivity
AT lacuranalecandere uncoveringmolecularbasesunderlyingbonemorphogeneticproteinreceptorinhibitorselectivity
AT oelschlaegerpeter uncoveringmolecularbasesunderlyingbonemorphogeneticproteinreceptorinhibitorselectivity
AT haojijun uncoveringmolecularbasesunderlyingbonemorphogeneticproteinreceptorinhibitorselectivity
AT luoyun uncoveringmolecularbasesunderlyingbonemorphogeneticproteinreceptorinhibitorselectivity